Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide survey

References

• Salvarani C, Pipitone N, Versari A, Hunder GG. Clinical features of polymyalgia rheumatica and giant cell arteritis. Nat Rev Rheumatol. 2012;8(9):509–11. doi:10.1038/nrrheum.2012.97.
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Yano T, Matsumoto Y, Numano F, Nakajima N, Yasuda K, Yutani C, Nakayama T, Tamakoshi A, Kawamura T. et al. Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: the first government-supported nationwide survey. Arthritis & Rheumatism. 2003;49(4):594–8. doi:10.1002/art.11195.
   PubMedGoogle Scholar
• Yates M, Graham K, Watts RA, MacGregor AJ. The prevalence of giant cell arteritis and polymyalgia rheumatica in a UK primary care population. BMC Musculoskelet Disord. 2016;17(1):285. doi:10.1186/s12891-016-1127-3.
   PubMedGoogle Scholar
• Zhang Z, Shen Q, Chang H. Vaccines for COVID-19: a systematic review of immunogenicity, current development, and future prospects. Front Immunol. 2022;13:843928. doi:10.3389/fimmu.2022.843928.
   PubMed Web of Science ®Google Scholar
• Lamprinou M, Sachinidis A, Stamoula E, Vavilis T, Papazisis G. COVID-19 vaccines adverse events: potential molecular mechanisms. Immunol Res. 2023;71(3):356–72. doi:10.1007/s12026-023-09357-5.
   PubMed Web of Science ®Google Scholar
• Mejren A, Sørensen CM, Gormsen LC, Tougaard RS, Nielsen BD. Large-vessel giant cell arteritis after COVID-19 vaccine. Scand J Rheumatol. 2022;51(2):154–5. doi:10.1080/03009742.2021.1961401.
   PubMed Web of Science ®Google Scholar
• Haruna K, Shirota S, Nishioka H. Polymyalgia Rheumatica (PMR) lacking shoulder pain following COVID-19 vaccination. Cureus. 2023;15:e34714. doi:10.7759/cureus.34714.
   PubMed Web of Science ®Google Scholar
• Mettler C, Jonville-Bera A-P, Grandvuillemin A, Treluyer J-M, Terrier B, Chouchana L. Risk of giant cell arteritis and polymyalgia rheumatica following COVID-19 vaccination: a global pharmacovigilance study. Rheumatology (Oxford). 2022;61(2):865–7. doi:10.1093/rheumatology/keab756.
   PubMed Web of Science ®Google Scholar
• Jonville-Bera AP, Gautier S, Micallef J, Massy N, Atzenhoffer M, Grandvuillemin A, Drici M-D. Monitoring the safety of drugs and COVID-19 vaccines by the French Pharmacovigilance Centers during the pandemic: a win-win bet with Health Authorities! Therapies. 2023;78(5):467–75. doi:10.1016/j.therap.2023.03.002.
   PubMedGoogle Scholar
• Dasgupta B, Cimmino MA, Maradit-Kremers H, Schmidt WA, Schirmer M, Salvarani C, Bachta A, Dejaco C, Duftner C, Jensen HS. et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2012;71(4):484–92. doi:10.1136/annrheumdis-2011-200329.
   PubMed Web of Science ®Google Scholar
• Ponte C, Grayson PC, Robson JC, Suppiah R, Gribbons KB, Judge A, Craven A, Khalid S, Hutchings A, Watts RA. et al. 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis. Ann Rheum Dis. 2022;81(12):1647–53. doi:10.1136/ard-2022-223480.
   PubMed Web of Science ®Google Scholar
• Greb CS, Aouhab Z, Sisbarro D, Panah E. A case of giant cell arteritis presenting after COVID-19 vaccination: is it just a coincidence? Cureus. 2022;14:e21608. doi:10.7759/cureus.21608.
   PubMed Web of Science ®Google Scholar
• Xia C, Edwards R, Omidvar B. A case of giant cell arteritis with a normal Erythrocyte Sedimentation Rate (ESR) post ChAdOx1 nCoV-19 vaccination. Cureus. 2022;14:e25388. doi:10.7759/cureus.25388.
   PubMed Web of Science ®Google Scholar
• Yamada S, Yamada K, Nishida H. A case of sequential development of polymyalgia rheumatica and guillain-barré syndrome following administration of the Pfizer-BioNTech COVID-19 vaccine. Intern Med. 2022;61(19):2995. doi:10.2169/internalmedicine.0319-22.
   PubMed Web of Science ®Google Scholar
• Ahmad A, Baker DL. An unusual side effect of the COVID-19 vaccine: a possible trigger of Polymyalgia Rheumatica. Cureus. 2022;14:e26617. doi:10.7759/cureus.26617.
   PubMed Web of Science ®Google Scholar
• Gambichler T, Krogias C, Tischoff I, Tannapfel A, Gold R, Susok L. Bilateral giant cell arteritis with skin necrosis following SARS-CoV-2 vaccination. Br J Dermatol. 2022;186(2):e83. doi:10.1111/bjd.20824.
   PubMed Web of Science ®Google Scholar
• Che S-A, Lee KY, Yoo Y-J. Bilateral ischemic optic neuropathy from giant cell arteritis following COVID-19 vaccination. J Neuroophthalmol. Published Online First: 14 June 2022. doi:10.1097/WNO.0000000000001570.
   Web of Science ®Google Scholar
• Hussain W, Moorthy A. Covid 19 vaccination -trigger for new onset polymyalgia rheumatica. Int J Rheum Dis. 2021;24:158–158.
   Google Scholar
• Ishizuka DK, Katayama K, Ohira Y. Giant cell arteritis presenting with chronic cough and headache after BNT162b2 mRNA COVID-19 vaccination. QJM. 2022;115(9):621–2. doi:10.1093/qjmed/hcac171.
   PubMed Web of Science ®Google Scholar
• Watad A, De Marco G, Mahajna H, Druyan A, Eltity M, Hijazi N, Haddad A, Elias M, Zisman D, Naffaa ME. et al. Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA/DNA SARS-CoV-2 vaccination. Vaccines. 2021;9(5):435. doi:10.3390/vaccines9050435.
   PubMed Web of Science ®Google Scholar
• Ursini F, Ruscitti P, Addimanda O, Foti R, Raimondo V, Murdaca G, Caira V, Pigatto E, Cuomo G, Lo Gullo A. et al. Inflammatory rheumatic diseases with onset after SARS-CoV-2 infection or COVID-19 vaccination: a report of 267 cases from the COVID-19 and ASD group. RMD Open. 2023;9(2):e003022. doi:10.1136/rmdopen-2023-003022.
   PubMed Web of Science ®Google Scholar
• Anzola AM, Trives L, Martínez-Barrio J, Pinilla B, Álvaro-Gracia JM, Molina-Collada J. New-onset giant cell arteritis following COVID-19 mRNA (BioNtech/Pfizer) vaccine: a double-edged sword? Clin Rheumatol. 2022;41(5):1623–5. doi:10.1007/s10067-021-06041-7.
   PubMed Web of Science ®Google Scholar
• Osada A, Sakuragi C, Toya C, Mitsuo A. New-onset polymyalgia rheumatica following the administration of the Pfizer-BioNTech COVID-19 vaccine. Intern Med. 2022;61(5):749–53. doi:10.2169/internalmedicine.8651-21.
   PubMed Web of Science ®Google Scholar
• Mohareb M, Bharadwaj A, Nandagudi A. P061 polymyalgia rheumatica following COVID-19 vaccination: presentation of four patients. Rheumatology (Oxford). 2022;61(Supplement_1):keac133.060. doi:10.1093/rheumatology/keac133.060.
   Google Scholar
• Lourenço C, Pascoal A, Paiva A, Campos, I, Pagaimo, J. 2022. Polymyalgia rheumatica after ChAdOx1 nCov-19 vaccine: a case report. Cureus. 14:e25346.
   PubMed Web of Science ®Google Scholar
• Manzo C, Castagna A, Isetta M. Polymyalgia rheumatica and polymyalgia-like syndromes as adverse events following COVID-19 vaccines: working notes from a narrative review of published literature. Reumatologia. 2022;60(2):142–7. doi:10.5114/reum.2022.115665.
   PubMed Web of Science ®Google Scholar
• Yokote A, Fujioka S, Takahashi N, Mishima T, Tsuboi Y. Polymyalgia rheumatica following COVID-19 vaccination. Intern Med. 2022;61(11):1775–7. doi:10.2169/internalmedicine.8934-21.
   PubMed Web of Science ®Google Scholar
• Furr T, Garg M. Rare cases of polymyalgia rheumatica after receiving COVID-19 vaccinations. Cureus. 2023;15(4):e37782. doi:10.7759/cureus.37782.
   PubMedGoogle Scholar
• Izuka S, Komai T, Natsumoto B, Shoda H, Fujio K. Self-limited polymyalgia rheumatica-like syndrome following mRNA-1273 SARS-CoV-2 vaccination. Intern Med. 2022;61(6):903–6. doi:10.2169/internalmedicine.8829-21.
   PubMed Web of Science ®Google Scholar
• Nielsen AW, Hansen IT, Gormsen LC, Hauge E-M, Keller KK. Self-limiting reactive disease mimicking polymyalgia rheumatica following moderna COVID-19 vaccine. Scand J Rheumatol. 2022;51(5):411–3. doi:10.1080/03009742.2022.2070959.
   PubMed Web of Science ®Google Scholar
• Thiele T, Weisser K, Schönborn L, Funk MB, Weber G, Greinacher A, Keller-Stanislawski B. Laboratory confirmed vaccine-induced immune thrombotic thrombocytopenia: retrospective analysis of reported cases after vaccination with ChAdOx-1 nCoV-19 in Germany. Lancet Reg Health Eur. 2022;12:100270. doi:10.1016/j.lanepe.2021.100270.
   PubMedGoogle Scholar
• Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Miranda‐Filloy JA, Gonzalez‐Juanatey C, Martin J, Llorca J. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis & Rheumatism. 2009;61(10):1454–61. doi:10.1002/art.24459.
   PubMedGoogle Scholar
• de Boysson H, Daumas A, Vautier M, Parienti J-J, Liozon E, Lambert M, Samson M, Ebbo M, Dumont A, Sultan A. et al. Large-vessel involvement and aortic dilation in giant-cell arteritis. A multicenter study of 549 patients. Autoimmun Rev. 2018;17(4):391–8. doi:10.1016/j.autrev.2017.11.029.
   PubMed Web of Science ®Google Scholar
• Toro-Gutiérrez CE, CañCañAs CA, Mantilla RD, Beltrán S, Pastrana-Gonzalez V, Vecino MJ, Rodriguez-Jimenez M, Rojas M. Polymyalgia rheumatica: a case series from Colombia and analysis of Latin America. J Transl Autoimmun. 2021;4:100115. doi:10.1016/j.jtauto.2021.100115.
   PubMedGoogle Scholar
• Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. 2002;347(4):261–71. doi:10.1056/NEJMra011913.
   PubMed Web of Science ®Google Scholar
• Dhamanti I, Suwantika AA, Adlia A, Yamani LN, Yakub F. Adverse reactions of COVID-19 vaccines: a scoping review of observational studies. Int J Gen Med. 2023;16:609–18. doi:10.2147/IJGM.S400458.
   PubMed Web of Science ®Google Scholar
• Soriano A, Muratore F, Pipitone N, Boiardi L, Cimino L, Salvarani C. Visual loss and other cranial ischaemic complications in giant cell arteritis. Nat Rev Rheumatol. 2017;13(8):476–84. doi:10.1038/nrrheum.2017.98.
   PubMed Web of Science ®Google Scholar
• Penet T, Lambert M, Baillet C, Outteryck O, Hénon H, Morell-Dubois S, Hachulla E, Launay D, Pokeerbux MR. Giant cell arteritis-related cerebrovascular ischemic events: a French retrospective study of 271 patients, systematic review of the literature and meta-analysis. Arthritis Res Ther. 2023;25(1):116. doi:10.1186/s13075-023-03091-x.
   PubMed Web of Science ®Google Scholar
• Greigert H, Zeller M, Putot A, Steinmetz E, Terriat B, Maza M, Falvo N, Muller G, Arnould L, Creuzot-Garcher C. et al. Myocardial infarction during giant cell arteritis: a cohort study. Eur J Intern Med. 2021;89:30–8. doi:10.1016/j.ejim.2021.02.001.
   PubMed Web of Science ®Google Scholar
• Soussan M, Nicolas P, Schramm C, Katsahian S, Pop G, Fain O, Mekinian A. Management of large-vessel vasculitis with FDG-PET: a systematic literature review and meta-analysis. Medicine (Baltimore). 2015;94(14):e622. doi:10.1097/MD.0000000000000622.
   PubMed Web of Science ®Google Scholar
• Prieto-González S, Arguis P, García-Martínez A, Espígol-Frigolé G, Tavera-Bahillo I, Butjosa M, Sánchez M, Hernández-Rodríguez J, Grau JM, Cid MC. et al. Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. Ann Rheum Dis. 2012;71(7):1170–6. doi:10.1136/annrheumdis-2011-200865.
   PubMed Web of Science ®Google Scholar
• Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, Cassie R, Cid MC, Dasgupta B, Dejaco C. et al. 2018 update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79(1):19–30. doi:10.1136/annrheumdis-2019-215672.
   PubMed Web of Science ®Google Scholar
• Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S, Abril A, Bachta A, Balint P, Barraclough K. et al. 2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2015;74(10):1799–807. doi:10.1136/annrheumdis-2015-207492.
   PubMed Web of Science ®Google Scholar
• Mackie SL, Dejaco C, Appenzeller S, Camellino D, Duftner C, Gonzalez-Chiappe S, Mahr A, Mukhtyar C, Reynolds G, de Souza AWS. et al. British society for rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology (Oxford). 2020;59(3):e1–23. doi:10.1093/rheumatology/kez672.
   PubMed Web of Science ®Google Scholar
• González-Gay MA, Matteson EL, Castañeda S. Polymyalgia rheumatica. Lancet. 2017;390(10103):1700–12. doi:10.1016/S0140-6736(17)31825-1.
   PubMed Web of Science ®Google Scholar
• Moreel L, Betrains A, Molenberghs G, Vanderschueren S, Blockmans D. Epidemiology and predictors of relapse in giant cell arteritis: a systematic review and meta-analysis. Joint Bone Spine. 2023;90(1):105494. doi:10.1016/j.jbspin.2022.105494.
   PubMed Web of Science ®Google Scholar
• Miller FW, Hess EV, Clauw DJ, Hertzman PA, Pincus T, Silver RM, Mayes MD, Varga J, Medsger TA, Love LA. et al. Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis & Rheumatism. 2000;43(2):243–9. doi:10.1002/1529-0131(200002)43:2<243:AID-ANR2>3.0.CO;2-K.
   PubMedGoogle Scholar
• Felicetti P, Trotta F, Bonetto C, Santuccio C, Brauchli Pernus Y, Burgner D, Chandler R, Girolomoni G, Hadden RDM, Kochhar S. et al. Spontaneous reports of vasculitis as an adverse event following immunization: a descriptive analysis across three international databases. Vaccine. 2016;34(51):6634–40. doi:10.1016/j.vaccine.2015.09.027.
   PubMed Web of Science ®Google Scholar
• Liozon E, Parreau S, Filloux M, Dumonteil S, Gondran G, Bezanahary H, Ly KH, Fauchais AL. Giant cell arteritis or polymyalgia rheumatica after influenza vaccination: a study of 12 patients and a literature review. Autoimmun Rev. 2021;20(2):102732. doi:10.1016/j.autrev.2020.102732.
   PubMed Web of Science ®Google Scholar
• Cohen Tervaert JW, Martinez-Lavin M, Jara LJ, Halpert G, Watad A, Amital H, Shoenfeld Y. Autoimmune/Inflammatory syndrome induced by adjuvants (ASIA) in 2023. Autoimmun Rev. 2023;22(5):103287. doi:10.1016/j.autrev.2023.103287.
   PubMed Web of Science ®Google Scholar
• Ndeupen S, Qin Z, Jacobsen S. et al. The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience. 2021;24:103479. doi:10.1016/j.isci.2021.103479.
   PubMed Web of Science ®Google Scholar
• Patra T, Meyer K, Geerling L, Isbell TS, Hoft DF, Brien J, Pinto AK, Ray RB, Ray R. SARS-CoV-2 spike protein promotes IL-6 trans-signaling by activation of angiotensin II receptor signaling in epithelial cells. PloS Pathog. 2020;16(12):e1009128. doi:10.1371/journal.ppat.1009128.
   PubMed Web of Science ®Google Scholar
• Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol. 2022;23(2):186–93. doi:10.1038/s41590-021-01122-w.
   PubMed Web of Science ®Google Scholar